Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.48), $0.08 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $5.9 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.